RDUS radiuspharm.com Net earnings per share for the last 12 months

Public company logo of Radius Recycling, Inc. (RDUS)

The 12-month earnings per share history for Radius Recycling, Inc. (RDUS) demonstrates stability, where the value of -3.60 expresses the metric level. Raw material supply for the clinic is secured through flexible delivery routes. The leadership of the drug Tymlos and innovative patches guarantee patient adherence in the US. Consequently, the biopharmaceutical ecosystem, supported by protected patents and B2B contracts, firmly maintains its market position.

RDUS (Radius Pharmaceuticals) Net earnings per share (EPS TTM) history from 07/04/2022 to 07/26/2025

Analytical breakdowns and data insights for company Radius Pharmaceuticals (RDUS)

- stock price and consensus target price:
Fundamental company valuation:Radius Recycling Inc. (RDUS)
Mass-produced product of Radius Health

Annual net earnings per share determine the portion of actual income attributable to a single security. Investors utilize this metric to assess real business efficiency and forecast capital growth rates. By analyzing the current EPS value over the last 12 months, one can determine the issuer's ability to generate profit amid volatility. Positive momentum confirms the resilience of Radius Recycling, Inc. (RDUS) as a major secondary raw materials operator. Stable industrial demand for metal provides the company with consistent turnover and fundamental revenue support.

Competitors of Radius Recycling, Inc.

Ascendis - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Madrigal Pharma|CORT (Corcept Therapeutics Incorporated) - Net earnings per share for the last 12 months|RYTM: Earnings per share for the last four quarters|AKRO (Akero Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Metsera Inc|Net earnings per share (EPS TTM) MLTX|Earnings per share for the last twelve months CRNX (Crinetics Pharmaceuticals, Inc.)|Earnings per share for the last twelve months newamsterdampharma.com NAMS|Soleno Therapeutics Corp (SLNO) - Net earnings per one share for the last twelve months|FOLD - Earnings per share for the last twelve months|ETNB: Earnings per share for the last twelve months|AGIO: Net earnings per share (EPS TTM)|GPCR - Net earnings per share for the last four quarters|Earnings per share for the last twelve months MiMedx Corp|Rezolute Bio (RZLT) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months lexpharma.com (LXRX)|Net earnings per share for the last 12 months MBX Biosciences Inc MBX|Earnings per share for the last twelve months Altimmune ALT|Net earnings per share (EPS TTM) Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BioAge Labs, Inc BIOA|Biomea Fusion Inc (BMEA) - Earnings per share for the last twelve months|QNCX - Net earnings per share for the last four quarters|GUTS (Fractyl Health Inc.) - Net earnings per share (EPS TTM)|VTVT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATPC|Net earnings per share for the last four quarters Pluri Inc|Net earnings per share (EPS TTM) SYBX (Synlogic Corp)|Net earnings per share for the last four quarters lipocine.com (LPCN)|MTNB - Earnings per share for the last twelve months|Earnings per share for the trailing year SPRB (Spruce Biosciences)|GLTO (Galecto Corp) - Net earnings per share for the last 12 months|Carmell Corp - Earnings per share for the trailing year|LUMO (Lumos Therapeutics) - Net earnings per share (EPS TTM)|ONVO: Earnings per share for the trailing year